The effects of reduced copayments on discontinuation and adherence failure to statin medication in Australia

Health Policy

Volumn 119, Issue 5, 2015, Pages 620-627

  Knott, Rachel J ^a,b   Petrie, Dennis J ^a   Heeley, Emma L ^c,d   Chalmers, John P ^c,d   Clarke, Philip M ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c GEORGE INSTITUTE FOR GLOBAL HEALTH   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Adherence; Australian pharmaceutical benefits scheme; Co payments; Discontinuation; Statins

Indexed keywords

FLUINDOSTATIN; PRAVASTATIN; SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; AUSTRALIA; CONTROLLED STUDY; DRUG COST; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICARE; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL; SMOKING; SOCIOECONOMICS; COST; ECONOMICS; HEALTH CARE COST; MIDDLE AGED; REIMBURSEMENT;

AGED; AUSTRALIA; DEDUCTIBLES AND COINSURANCE; FEMALE; HEALTH EXPENDITURES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; INSURANCE, HEALTH, REIMBURSEMENT; MALE; MEDICATION ADHERENCE; MIDDLE AGED;

EID: 84933679690     PISSN: 01688510     EISSN: 18726054     Source Type: Journal    
DOI: 10.1016/j.healthpol.2015.01.003     Document Type: Article

References (30)

1. Australian Bureau of Statistics Cause of death, Australia 2010 2011, ABS, Canberra, (ABS Catalogue No. 3303.0). http://www.abs.gov.au/ausstats/abs@.nsf/Products/6BAD463E482C6970CA2579C6000F6AF7?opendocument [accessed April 2014].
2. Clarke P. The price is wrong: pharmaceutical expenditure in Australia over the last decade and options for reform 2013, 48. Reform or Ration, CEDA, Healthcare.
3. Brugts J.J., Yetgin T., Hoeks S.E., Gotto A.M., Shepherd J., Westendorp R.G., et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 2009, 338.
4. Simons L.A., Levis G., Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Medical Journal of Australia 1996, 164:208-211.
5. Simons Leon A., Ortiz M., Calcino G. Long term persistence with statin therapy: experience in Australia 2006-2010. Australian Family Physician 2011, 40(5):319.
6. Sokol M.C., McGuigan K.A., Verbrugge R.R., Epstein R.S. Impact of medication adherence on hospitalization risk and healthcare cost. Medical Care 2005, 43(6):521-530.
7. Simons L.A., Ortiz M., Calcino G. Persistence with a single pill versus two pills of amlodipine and atorvastatin: the Australian experience, 2006-2010. Medical Journal of Australia 2001, 195(3):134-137.
8. Taira D.A., Wong K.S., Frech-Tamas F., Chung R.S. Copayment level and compliance with antihypertensive medication: analysis and policy implications for managed care. American Journal of Managed Care 2006, 12(11):678.
9. Schneeweiss S., Patrick A.R., Maclure M., Dormuth C.R., Glynn R.J. Adherence to statin therapy under drug cost sharing in patients with and without acute myocardial infarction A population-based natural experiment. Circulation 2007, 115(16):2128-2135.
10. Hsu J., Price M., Huang J., Brand R., Fung V., Hui R., et al. Unintended consequences of caps on Medicare drug benefits. New England Journal of Medicine 2006, 354(22):2349-2359.
11. Barros P., Siciliani L. Public and private sector interface. Handbook of Health Economics 2012, 2:927-1002.
12. Kemp A., Preen D.B., Glover J., Semmens J., Roughead E.E. How much do we spend on prescription medicines? Out-of-pocket costs for patients in Australia and other OECD countries. Australian Health Review 2011, 35(3):341-349.
13. Australian Bureau of Statistics Year book Australia 2009-10 2010, ABS, Canberra, (ABS Cat. No. 1301.0.).
14. Heeley E.L., Peiris D.P., Patel A.A., Cass A., Weekes A., Morgan C., et al. Cardiovascular risk perception and evidence-practice gaps in Australian general practice (the AusHEART study). Medical Journal of Australia 2010, 192(5):254-259.
15. Knott R.J., Cass A., Heeley E.L., Chalmers J.P., Peiris D.P., Clarke P.M. How fair is Medicare? The income-related distribution of Medicare benefits with special focus on chronic care items. Medical Journal of Australia 2012, 197(11):625-630.
16. Hagenaars A., de Vos K., Zaidi M.A. Poverty statistics in the late 1980: research based on micro-data 1994, Office for Official Publications of the European Community, Luxembourg.
17. Australian Bureau of Statistics 2011 Australian Standard Geographical Classification (ASGC) remoteness area correspondences 2006, ABS, Canberra, Cat. No. 1216.0.15.003.
18. Australian Government Department of Health and Ageing Expenditure and prescriptions twelve months to 30 June 2011 2011, http://www.health.gov.au/internet/main/publishing.nsf/Content/99A860532C73A1EFCA257947008239E8/$File/A%20Expenditure%20and%20prescriptions%2012%20mths%20to%2030%20June%202011.pdf [accessed April 2014].
19. Benner J.S., Glynn R.J., Mogun H., Neumann P., Weinstein M.C., Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002, 288(4):455-461.
20. Wood B. Medication Adherence: the real problem when treating chronic conditions. US Pharmacist 2012, 37(4):3-6.
21. McCowan C., Wang S., Thompson A.M., Makubate B., Petrie D.J. The value of high adherence to tamoxifen in women with breast cancer: a community based cohort study. British Journal of Cancer 2013, 109:1172-1180.
22. Hynd A., Roughead E.E., Preen D.B., Glover J., Bulsara M., Semmens J. The impact of co-payment increases on dispensings of government-subsidised medicines in Australia. Pharmacoepidemiology and Drug Safety 2008, 17(11):1091-1099.
23. Clarke P.M., Fitzgerald E.M. Expiry of patent protection on statins: effects on pharmaceutical expenditure in Australia. Medical Journal of Australia 2010, 192:633-636.
24. National Commission of Audit.7.4 The Pharmaceutical Benefits Scheme Towards Responsible Government, The Report of the National Commission of Audit - Phase One 2014, March, [accessed April 2014]. http://www.ncoa.gov.au/report/index.html.
25. Simons Leon A., Michael Ortiz, Gordon Calcino Persistence with antihypertensive medication: Australia-wide experience, 2004-2006. Medical Journal of Australia 2008, 188(4):224.
26. Jackevicius C.A., Mamdani M., Tu J.V. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. Jama 2002, 288(4):462-467.
27. Ellis J.J., Erickson S.R., Stevenson J.G., Bernstein S.J., Stiles R.A., Fendrick A.M. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. Journal of general internal medicine 2004, 19(6):638-645.
28. Cox E., Martin B.C., Van Staa T., Garbe E., Siebert U., Johnson M.L. Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: the International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report-Part II. Value in Health 2009, 12(8):1053-1061.
29. Ray W.A. Evaluating medication effects outside of clinical trials: new-user designs. American journal of epidemiology 2003, 158(9):915-920.
30. Helin-Salmivaara A., Lavikainen P., Korhonen M.J., Halava H., Junnila S.Y., Kettunen R., et al. Long-term persistence with statin therapy: a nationwide register study in Finland. Clinical therapeutics 2008, 30:2228-2240.